$599

Alnylam and Regeneron to Advance NASH ALN-HSD Asset

Alnylam and Regeneron announced initial Part B data from the ALN-HSD Ph1 NASH study (view CT.gov record) and disclosed plans to initiate Ph2 development in late 2022. Recall, during its November 2021 R&D webinar, Alnylam highlighted 14-week HSD17B13 knockdown results from Part A of the ALN-HSD Ph1 study (previous FENIX insight). Below, FENIX provides context and insight on the latest ALN-HSD data readout.

This content is for Read Less members only.
Register
Already a member? Log in here